Telbermin

Drug Profile

Telbermin

Alternative Names: Recombinant VEGF - Genentech; Recombinant VEGF165; rhVEGF165; Vascular endothelial growth factor 165 - Genentech

Latest Information Update: 18 Jan 2008

Price : $50

At a glance

  • Originator Genentech
  • Class Growth factors
  • Mechanism of Action Angiogenesis inducing agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic foot ulcer; Myocardial ischaemia

Most Recent Events

  • 29 Nov 2001 Discontinued - Phase-II for Myocardial ischaemia in USA (Parenteral)
  • 17 May 2000 Two studies have been added to the Ischaemic Heart Disease pharmacodynamics section ,
  • 03 Jun 1999 A study has been added to the Ischaemic Heart Disease therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top